Similar articles

• Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.

  Miller AB, Klaassen DJ, Boyes DA, Dodds DJ, Gerulath A, Kirk ME, Levitt M, Pearson JG, Wall C. Miller AB, et al. Can Med Assoc J. 1980 Sep 6;123(5):365-71. Can Med Assoc J. 1980. PMID: 7020903 Free PMC article. Clinical Trial.
• Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.

  Bruckner HW, Pagano M, Falkson G, Creech R, Arseneau JC, Horton J, Brodovsky H, Davis TE, Slayton RW, Greenspan E. Bruckner HW, et al. Cancer Treat Rep. 1979 Feb;63(2):297-9. Cancer Treat Rep. 1979. PMID: 376136 Clinical Trial. No abstract available.
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT Jr. Young RC, et al. N Engl J Med. 1978 Dec 7;299(23):1261-6. doi: 10.1056/NEJM197812072992301. N Engl J Med. 1978. PMID: 101843 Clinical Trial.
• Recent progress in breast cancer management. Combined modality (adjuvant) therapy.

  Cowan K, Lippman M. Cowan K, et al. Arch Intern Med. 1981 Jul;141(8):1055-9. Arch Intern Med. 1981. PMID: 7018440 Review. No abstract available.
• Advances in the multimodal primary management of cancer.

  DeVita VT Jr, Henney JE, Weiss RB. DeVita VT Jr, et al. Adv Intern Med. 1980;26:115-29. Adv Intern Med. 1980. PMID: 7013437 Review. No abstract available.